At a glance
ClinicalIndex Comparison Record- ✓Histologically or cytologically confirmed high-risk adenocarcinoma of the prostate
- ✓Clinical stage D2 disease evidenced by visceral disease (liver, lung, or other viscera) OR bone metastases in both axial (spine, pelvis, ribs, skull) and appendicular (claviculae, humeri, femora) skeleton
- ✓Age over 18 years
- ✓Zubrod performance status 0-2
- ✕Prior or concurrent (treated or untreated) brain metastases
- ✕Evidence of untreated spinal cord compression
- ✕Transient ischemic attack, stroke, or myocardial infarction within past 6 months
- ✕Active coronary artery disease requiring antianginal therapy
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Evaluation of Early Oral Estramustine, Oral Etoposide and Intravenous Paclitaxel in Combination With Hormone Therapy in Patients With High-Risk Metastatic Adenocarinoma of the Prostate
In Brief
A Phase 2 clinical trial evaluating bicalutamide, estramustine, and 6 other interventions for Prostate Cancer. Completed, enrolled 41 participants across 91 sites.
Detailed Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Androgens can stimulate the growth of prostate cancer cells. Drugs such as goserelin, leuprolide, flutamide, or bicalutamide may stop the adrenal glands from producing androgens. Combining chemotherapy with hormone therapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy plus hormone therapy in treating patients who have metastatic prostate cancer.